DAR3DouglasRubinsonDouglas Adam Rubinson, M.D., Ph.D.42.33510370000000-71.1061649000000035267Rubinson, DouglasAdamBoard certified medical oncologist specializing in gastrointestinal malignancies617/632-4405Assistant Professor of Medicinecatalyst:eCommonsLogineCommons Loginprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:overviewoverviewvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 1047116929474971Hamada T, Khalaf N, Yuan C, Morales-Oyarvide V, Babic A, Nowak JA, Qian ZR, Ng K, Rubinson DA, Kraft P, Giovannucci EL, Stampfer MJ, Fuchs CS, Ogino S, Wolpin BMClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationPrediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018 08; 16(8):1300-1306.e3.Clin Gastroenterol Hepatol2018-02-21T00:00:002018Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer.15709955Dillon CP, Sandy P, Nencioni A, Kissler S, Rubinson DA, Van Parijs LAnnual review of physiologyRnai as an experimental and therapeutic tool to study and regulate physiological and disease processes. Annu Rev Physiol. 2005; 67:147-73.Annu Rev Physiol2005-01-01T00:00:002005Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes.Authorship 1061298829691365Babic A, Schnure N, Neupane NP, Zaman MM, Rifai N, Welch MW, Brais LK, Rubinson DA, Morales-Oyarvide V, Yuan C, Zhang S, Poole EM, Wolpin BM, Kulke MH, Barbie DA, Wong K, Fuchs CS, Ng KClinical and translational gastroenterologyPlasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol. 2018 04 25; 9(4):145.Clin Transl Gastroenterol2018-04-25T00:00:002018Plasma inflammatory cytokines and survival of pancreatic cancer patients.Authorship 106263417998398Furman C, Sieminski AL, Kwiatkowski AV, Rubinson DA, Vasile E, Bronson RT, Fässler R, Gertler FBThe Journal of cell biologyEna/VASP is required for endothelial barrier function in vivo. J Cell Biol. 2007 Nov 19; 179(4):761-75.J Cell Biol2007-11-12T00:00:002007Ena/VASP is required for endothelial barrier function in vivo.Authorship 10739713629903880Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BMCancer discoveryReal-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.Cancer Discov2018-06-14T00:00:002018Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.Authorship 1077932429961768Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BMGenetics in medicine : official journal of the American College of Medical GeneticsGermline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.Genet Med2018-07-02T00:00:002018Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.14657028Chakshusmathi G, Kim SD, Rubinson DA, Wolin SLThe EMBO journalA La protein requirement for efficient pre-tRNA folding. EMBO J. 2003 Dec 15; 22(24):6562-72.EMBO J2003-12-15T00:00:002003A La protein requirement for efficient pre-tRNA folding.15469845Krause M, Leslie JD, Stewart M, Lafuente EM, Valderrama F, Jagannathan R, Strasser GA, Rubinson DA, Liu H, Way M, Yaffe MB, Boussiotis VA, Gertler FBDevelopmental cellLamellipodin, an Ena/VASP ligand, is implicated in the regulation of lamellipodial dynamics. Dev Cell. 2004 Oct; 7(4):571-83.Dev Cell2004-10-01T00:00:002004Lamellipodin, an Ena/VASP ligand, is implicated in the regulation of lamellipodial dynamics.Authorship 1178846Authorship 1139652930867564Hamada T, Yuan C, Yurgelun MB, Perez K, Khalaf N, Morales-Oyarvide V, Babic A, Nowak JA, Rubinson DA, Giannakis M, Ng K, Kraft P, Stampfer MJ, Giovannucci EL, Fuchs CS, Ogino S, Wolpin BMBritish journal of cancerFamily history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer. 2019 04; 120(8):848-854.Br J Cancer2019-03-14T00:00:002019Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk.D000230Disorders162263180.278905AdenocarcinomaD021441Disorders46416070.444774Carcinoma, Pancreatic DuctalD059016Phenomena131635080.407269Tumor MicroenvironmentD010190Disorders118452130.279031Pancreatic NeoplasmsD000971Procedures1751114100.225091Antineoplastic Combined Chemotherapy ProtocolsAuthorship 11460727Authorship 1147633730964527Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CSJAMAEffect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019 04 09; 321(14):1370-1379.JAMA2019-04-09T00:00:002019Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.30913304Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PCCancerFOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221.Cancer2019-03-26T00:00:002019FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.MedicinePathologyRadiation OncologySurgeryOncologyDana-Farber Cancer InstituteMassachusetts General HospitalMBY2MatthewYurgelunMatthew Boland Yurgelun, M.D.42.34022770000000-71.1058540000000071749Yurgelun, MatthewAssociate Professor of MedicineJL240JacobLaubachJacob Laubach, M.D.42.33510370000000-71.1061649000000046718Laubach, JacobAssociate Professor of MedicineHS149HarshabadSinghHarshabad Singh, M.B.,B.S.42.36125700000000-71.0655270000000068222Singh, HarshabadAssistant Professor of MedicineJMC35JamesClearyJames Mark Cleary, M.D., Ph.D.42.33789600000000-71.1072493000000062458Cleary, JamesAssociate Professor of MedicineEHS4ElizabethStoverElizabeth Harmon Stover, M.D., Ph.D.42.33510370000000-71.1061649000000024452Stover, ElizabethAssistant Professor of MedicineCJG13ChristopherGibsonChristopher James Gibson, M.D.42.33510370000000-71.1061649000000019903Gibson, ChristopherAssistant Professor of MedicineMM4MariMino-KenudsonMari Mino-Kenudson, M.D.42.36241700000000-71.0689370000000038437Mino-Kenudson, MariProfessor of PathologyKN38KimmieNgKimmie Ng, M.D.42.33789600000000-71.1072493000000046248Ng, KimmieAssociate Professor of MedicineALW2AndrewWarshawAndrew Louis Warshaw, M.D.42.36241700000000-71.0689370000000060108Warshaw, AndrewW. Gerald Austen Distinguished Professor of Surgery1162selected publications1.59780.00418524283research areas3.04960.0161956125coauthor of32.07786.3838260similar toKDL10KeithLillemoeKeith Douglas Lillemoe, M.D.99812Lillemoe, KeithW. Gerald Austen Professor of SurgeryBLE2BenjaminEbertBenjamin L. Ebert, D.Phil., M.D.42.33510370000000-71.1061649000000054850Ebert, BenjaminGeorge P. Canellos, MD, and Jean S. Canellos Professor of MedicineAJA4AndrewAguirreAndrew James Aguirre, M.D., Ph.D.42.33986200000000-71.104732000000002391Aguirre, AndrewAssociate Professor of MedicineTSH4TheodoreHongTheodore Sunki Hong, M.D.42.36389900000000-71.0677780000000066373Hong, TheodoreProfessor of Radiation OncologyMRL11MarliseLuskinMarlise Rachael Luskin, M.D.42.33510370000000-71.1061649000000010165Luskin, MarliseAssistant Professor of Medicinetrue1Professor of Radiation OncologyProfessor of Radiation Oncologytrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1W. Gerald Austen Distinguished Professor of SurgeryW. Gerald Austen Distinguished Professor of Surgerytrue1Professor of PathologyProfessor of Pathologytrue1George P. Canellos, MD, and Jean S. Canellos Professor of MedicineGeorge P. Canellos, MD, and Jean S. Canellos Professor of MedicineAuthorship 1524193true1Assistant Professor of MedicineAssistant Professor of MedicineAuthorship 1251127732467349Du C, da Silva A, Morales-Oyarvide V, Dias Costa A, Kozak MM, Dunne RF, Rubinson DA, Perez K, Masugi Y, Hamada T, Brais LK, Yuan C, Babic A, Ducar MD, Thorner AR, Aguirre A, Kulke MH, Ng K, Clancy TE, Findeis-Hosey JJ, Chang DT, Hornick JL, Fuchs CS, Ogino S, Koong AC, Hezel AF, Wolpin BM, Nowak JACancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyInsulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1586-1595.Cancer Epidemiol Biomarkers Prev2020-05-28T00:00:002020Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma.32789511Yuan C, Babic A, Khalaf N, Nowak JA, Brais LK, Rubinson DA, Ng K, Aguirre AJ, Pandharipande PV, Fuchs CS, Giovannucci EL, Stampfer MJ, Rosenthal MH, Sander C, Kraft P, Wolpin BMJAMA oncologyDiabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncol. 2020 10 01; 6(10):e202948.JAMA Oncol2020-10-01T00:00:002020Diabetes, Weight Change, and Pancreatic Cancer Risk.Authorship 12769536true1Associate Professor of SurgeryAssociate Professor of SurgeryAuthorship 13046921033233566Brown JC, Rosenthal MH, Ma C, Zhang S, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin B, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Zheng H, Hollis BW, Fuchs CS, Ng K, Meyerhardt JACancersEffect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. Cancers (Basel). 2020 Nov 20; 12(11).Cancers (Basel)2020-11-20T00:00:002020Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial.33262135Väyrynen SA, Zhang J, Yuan C, Väyrynen JP, Dias Costa A, Williams H, Morales-Oyarvide V, Lau MC, Rubinson DA, Dunne RF, Kozak MM, Wang W, Agostini-Vulaj D, Drage MG, Brais L, Reilly E, Rahma O, Clancy T, Wang J, Linehan DC, Aguirre AJ, Fuchs CS, Coussens LM, Chang DT, Koong AC, Hezel AF, Ogino S, Nowak JA, Wolpin BMClinical cancer research : an official journal of the American Association for Cancer ResearchComposition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clin Cancer Res. 2021 02 15; 27(4):1069-1081.Clin Cancer Res2020-12-01T00:00:002020Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer.Authorship 13091739Authorship 1333453333638680Khayat-Khoei M, Conway S, Rubinson DA, Jarolim P, Houtchens MKJournal of neurologyNegative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab. J Neurol. 2021 Oct; 268(10):3592-3594.J Neurol2021-02-27T00:00:002021Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.Authorship 13390671633727309Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Dias Costa A, Väyrynen SA, Clancy TE, Rubinson DA, Link J, Keith D, Horton W, Tempero MA, Vonderheide RH, Jaffee EM, Sheppard B, Goecks J, Sears RC, Park BS, Mori M, Nowak JA, Wolpin BM, Coussens LMCancer discoveryLeukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discov. 2021 08; 11(8):2014-2031.Cancer Discov2021-03-16T00:00:002021Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.33926920Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, Schrag D, Jänne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BMCancer discoveryFGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 10; 11(10):2488-2505.Cancer Discov2021-04-29T00:00:002021FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.Authorship 13515887Authorship 1358331834023183Sridharan V, Mino-Kenudson M, Cleary JM, Rahma OE, Perez K, Clark JW, Clancy TE, Rubinson DA, Goyal L, Bazerbachi F, Visrodia KH, Qadan M, Parikh A, Ferrone CR, Casey BW, Fernandez-Del Castillo C, Ryan DP, Lillemoe KD, Warshaw AL, Krishnan K, Hernandez-Barco YGPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021 May 15.Pancreatology2021-05-15T00:00:002021Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.Authorship 13988401134593617de Klerk LK, Patel AK, Derks S, Pectasides E, Augustin J, Uduman M, Raman N, Akarca FG, McCleary NJ, Cleary JM, Rubinson DA, Clark JW, Fitzpatrick B, Brais LK, Cavanaugh ME, Rode AJ, Jean MG, Lizotte PH, Nazzaro MJ, Severgnini M, Zheng H, Fuchs CS, Enzinger PC, Bass AJJournal for immunotherapy of cancerPhase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. J Immunother Cancer. 2021 09; 9(9).J Immunother Cancer2021-09-01T00:00:002021Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.34890551Raghavan S, Winter PS, Navia AW, Williams HL, DenAdel A, Lowder KE, Galvez-Reyes J, Kalekar RL, Mulugeta N, Kapner KS, Raghavan MS, Borah AA, Liu N, Väyrynen SA, Costa AD, Ng RWS, Wang J, Hill EK, Ragon DY, Brais LK, Jaeger AM, Spurr LF, Li YY, Cherniack AD, Booker MA, Cohen EF, Tolstorukov MY, Wakiro I, Rotem A, Johnson BE, McFarland JM, Sicinska ET, Jacks TE, Sullivan RJ, Shapiro GI, Clancy TE, Perez K, Rubinson DA, Ng K, Cleary JM, Crawford L, Manalis SR, Nowak JA, Wolpin BM, Hahn WC, Aguirre AJ, Shalek AKCellMicroenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021 12 09; 184(25):6119-6137.e26.Cell2021-12-09T00:00:002021Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer.Authorship 141792338Authorship 1427644135070436Rubinson D, Wolpin BM, Warsofsky IS, Ryan DP, Perez K, Rahma O, Singh H, Yurgelun MB, Shapiro GI, Aguirre AJ, D'Andrea AD, Cleary JMJournal of gastrointestinal oncologyDurable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. J Gastrointest Oncol. 2021 Dec; 12(6):3133-3140.J Gastrointest Oncol2021-12-01T00:00:002021Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report.Authorship 1449520435380713Lipsyc-Sharf M, Ou FS, Yurgelun MB, Rubinson DA, Schrag D, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng KThe oncologistCetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. Oncologist. 2022 04 05; 27(4):292-298.Oncologist2022-04-05T00:00:002022Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.Authorship 1462375935722047Brown JC, Brighton E, Campbell N, McCleary NJ, Abrams TA, Cleary JM, Enzinger PC, Ng K, Rubinson D, Wolpin BM, Yurgelun MB, Meyerhardt JABMJ open sport & exercise medicinePhysical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. BMJ Open Sport Exerc Med. 2022; 8(2):e001353.BMJ Open Sport Exerc Med2022-05-30T00:00:002022Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study.true1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 4334993Authorship 149112919Authorship 15031502Authorship 1492197136129461Dias Costa A, Väyrynen SA, Chawla A, Zhang J, Väyrynen JP, Lau MC, Williams HL, Yuan C, Morales-Oyarvide V, Elganainy D, Singh H, Cleary JM, Perez K, Ng K, Freed-Pastor W, Mancias JD, Dougan SK, Wang J, Rubinson DA, Dunne RF, Kozak MM, Brais L, Reilly E, Clancy T, Linehan DC, Chang DT, Hezel AF, Koong AC, Aguirre AJ, Wolpin BM, Nowak JAClinical cancer research : an official journal of the American Association for Cancer ResearchNeoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Clin Cancer Res. 2022 12 01; 28(23):5167-5179.Clin Cancer Res2022-12-01T00:00:002022Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer.36265995Rubinson DA, Yurgelun MBHematology/oncology clinics of North AmericaPreface. Hematol Oncol Clin North Am. 2022 Oct; 36(5):xiii-xiv.Hematol Oncol Clin North Am2022-10-01T00:00:002022Preface.36334860DeRidder L, Rubinson DA, Langer R, Traverso GJournal of controlled release : official journal of the Controlled Release SocietyThe past, present, and future of chemotherapy with a focus on individualization of drug dosing. J Control Release. 2022 Dec; 352:840-860.J Control Release2022-11-14T00:00:002022The past, present, and future of chemotherapy with a focus on individualization of drug dosing.true1Assistant Professor of MedicineAssistant Professor of MedicineAuthorship 15068182036459568Williams HL, Dias Costa A, Zhang J, Raghavan S, Winter PS, Kapner KS, Ginebaugh SP, Väyrynen SA, Väyrynen JP, Yuan C, Navia AW, Wang J, Yang A, Bosse TL, Kalekar RL, Lowder KE, Lau MC, Elganainy D, Morales-Oyarvide V, Rubinson DA, Singh H, Perez K, Cleary JM, Clancy TE, Wang J, Mancias JD, Brais LK, Hill ER, Kozak MM, Linehan DC, Dunne RF, Chang DT, Koong AC, Hezel AF, Hahn WC, Shalek AK, Aguirre AJ, Nowak JA, Wolpin BMCancer researchSpatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Cancer Res. 2023 02 03; 83(3):441-455.Cancer Res2023-02-03T00:00:002023Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity.36551707Huffman BM, Ellis H, Jordan AC, Freed-Pastor WA, Perez K, Rubinson DA, Sethi N, Singh H, Surana R, Wolpin BM, Aguirre AJ, Cleary JMCancersEmerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers (Basel). 2022 Dec 16; 14(24).Cancers (Basel)2022-12-16T00:00:002022Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma.Authorship 15118306Authorship 15169623436634297Keller RB, Mazor T, Sholl L, Aguirre AJ, Singh H, Sethi N, Bass A, Nagaraja AK, Brais LK, Hill E, Hennessey C, Cusick M, Del Vecchio Fitz C, Zwiesler Z, Siegel E, Ovalle A, Trukhanov P, Hansel J, Shapiro GI, Abrams TA, Biller LH, Chan JA, Cleary JM, Corsello SM, Enzinger AC, Enzinger PC, Mayer RJ, McCleary NJ, Meyerhardt JA, Ng K, Patel AK, Perez KJ, Rahma OE, Rubinson DA, Wisch JS, Yurgelun MB, Hassett MJ, MacConaill L, Schrag D, Cerami E, Wolpin BM, Nowak JA, Giannakis MJCO precision oncologyProgrammatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer. JCO Precis Oncol. 2023 01; 7:e2200342.JCO Precis Oncol2023-01-01T00:00:002023Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.true1Associate Professor of MedicineAssociate Professor of Medicinetrue1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 15267981236807743Perez K, Chiarella AM, Cleary JM, Horick N, Weekes C, Abrams T, Blaszkowsky L, Enzinger P, Giannakis M, Goyal L, Meyerhardt JA, Rubinson D, Yurgelun MB, Goessling W, Giantonio BJ, Brais L, Germon V, Stonely D, Raghavan S, Bakir B, Das K, Pitarresi JR, Aguirre AJ, Needle M, Rustgi AK, Wolpin BMThe oncologistPhase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Oncologist. 2023 05 08; 28(5):425-432.Oncologist2023-05-08T00:00:002023Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer.true1Assistant Professor of MedicineAssistant Professor of Medicine37030295Perurena N, Lock R, Davis RA, Raghavan S, Pilla NF, Ng R, Loi P, Guild CJ, Miller AL, Sicinska E, Cleary JM, Rubinson DA, Wolpin BM, Gray NS, Santagata S, Hahn WC, Morton JP, Sansom OJ, Aguirre AJ, Cichowski KCell reports. MedicineUSP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell Rep Med. 2023 04 18; 4(4):101007.Cell Rep Med2023-04-07T00:00:002023USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.Authorship 156407314Authorship 156290712Authorship 155643313Authorship 1563871837343200Singh H, Klempner SJ, Melnitchouk N, Chander DP, Negrea OG, Patel AK, Schlechter BL, Rubinson DA, Huffman BM, Nambiar C, Remland J, Andrews E, Leahy ME, Brais LK, Enzinger PC, Mamon HJ, Giannakis M, Meyerhardt JA, Ng K, Perez KJ, Aguirre AJ, Clark JW, Cleary JM, Wolpin BMJCO precision oncologyHighly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer. JCO Precis Oncol. 2023 06; 7:e2200572.JCO Precis Oncol2023-06-01T00:00:002023Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer.37344102Cardot-Ruffino V, Bollenrucher N, Delius L, Wang SJ, Brais LK, Remland J, Keheler CE, Sullivan KM, Abrams TA, Biller LH, Enzinger PC, McCleary NJ, Patel AK, Rubinson DA, Schlechter B, Slater S, Yurgelun MB, Cleary JM, Perez K, Dougan M, Ng K, Wolpin BM, Singh H, Dougan SKJournal for immunotherapy of cancerG-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans. J Immunother Cancer. 2023 06; 11(6).J Immunother Cancer2023-06-01T00:00:002023G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.37463056Singh H, Keller RB, Kapner KS, Dilly J, Raghavan S, Yuan C, Cohen EF, Tolstorukov M, Andrews E, Brais LK, da Silva A, Perez K, Rubinson DA, Surana R, Giannakis M, Ng K, Clancy TE, Yurgelun MB, Schlechter BL, Clark JW, Shapiro GI, Rosenthal MH, Hornick JL, Nardi V, Li YY, Gupta H, Cherniack AD, Meyerson M, Cleary JM, Nowak JA, Wolpin BM, Aguirre AJClinical cancer research : an official journal of the American Association for Cancer ResearchOncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Clin Cancer Res. 2023 Nov 14; 29(22):4627-4643.Clin Cancer Res2023-11-14T00:00:002023Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.Authorship 15838041037763145Barzi A, Kim AJ, Liang CK, West H, Wong D, Wright C, Nathwani N, Vasko CM, Chung V, Rubinson DA, Sachs TJournal of personalized medicinePancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data. J Pers Med. 2023 Sep 15; 13(9).J Pers Med2023-09-15T00:00:002023Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data.37819936Huffman BM, Feng H, Parmar K, Wang J, Kapner KS, Kochupurakkal B, Martignetti DB, Sadatrezaei G, Abrams TA, Biller LH, Giannakis M, Ng K, Patel AK, Perez KJ, Singh H, Rubinson DA, Schlechter BL, Andrews E, Hannigan AM, Dunwell S, Getchell Z, Raghavan S, Wolpin BM, Fortier C, D'Andrea AD, Aguirre AJ, Shapiro GI, Cleary JMClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Clin Cancer Res. 2023 Dec 15; 29(24):5047-5056.Clin Cancer Res2023-12-15T00:00:002023A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.Authorship 159709116true1W. Gerald Austen Professor of SurgeryW. Gerald Austen Professor of SurgeryAuthorship 16146542638123998Ben-Ami R, Wang QL, Zhang J, Supplee JG, Fahrmann JF, Lehmann-Werman R, Brais LK, Nowak J, Yuan C, Loftus M, Babic A, Irajizad E, Davidi T, Zick A, Hubert A, Neiman D, Piyanzin S, Gal-Rosenberg O, Horn A, Shemer R, Glaser B, Boos N, Jajoo K, Lee L, Clancy TE, Rubinson DA, Ng K, Chabot JA, Kastrinos F, Kluger M, Aguirre AJ, Jänne PA, Bardeesy N, Stanger B, O'Hara MH, Till J, Maitra A, Carpenter EL, Bullock AJ, Genkinger J, Hanash SM, Paweletz CP, Dor Y, Wolpin BMGutProtein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2024 Mar 07; 73(4):639-648.Gut2024-03-07T00:00:002024Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer.Authorship 1621749138236605Rubinson DA, Tanaka N, Fece de la Cruz F, Kapner KS, Rosenthal MH, Norden BL, Barnes H, Ehnstrom S, Morales-Giron AA, Brais LK, Lemke CT, Aguirre AJ, Corcoran RBCancer discoverySotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRASG12C cancers. Cancer Discov. 2024 Jan 18.Cancer Discov2024-01-18T00:00:002024Sotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRASG12C cancers.Authorship 16239173338272561Huffman BM, Singh H, Ali LR, Horick N, Wang SJ, Hoffman MT, Metayer KA, Murray S, Bird A, Abrams TA, Biller LH, Chan JA, Meyerhardt JA, McCleary NJ, Goessling W, Patel AK, Wisch JS, Yurgelun MB, Mouw K, Reardon B, Van Allen EM, Zerillo JA, Clark JW, Parikh A, Mayer RJ, Schlechter B, Ng K, Kumar S, Del Vecchio Fitz C, Kuperwasser C, Hanna GJ, Coveler AL, Rubinson DA, Welsh EL, Pfaff K, Rodig S, Dougan SK, Cleary JMJournal for immunotherapy of cancerBiomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders. J Immunother Cancer. 2024 Jan 25; 12(1).J Immunother Cancer2024-01-25T00:00:002024Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.38345769Singh H, Sahgal P, Kapner K, Corsello SM, Gupta H, Gujrathi R, Li YY, Cherniack AD, El Alam R, Kerfoot J, Andrews E, Lee A, Nambiar C, Hannigan AM, Remland J, Brais L, Leahy ME, Rubinson DA, Schlechter BL, Meyerson M, Kuang Y, Paweletz CP, Lee JK, Quintanilha JCF, Aguirre AJ, Perez KJ, Huffman BM, Rossi H, Abrams TA, Kabraji S, Trusolino L, Bertotti A, Sicinska ET, Parikh AR, Wolpin BM, Schrock AB, Giannakis M, Ng K, Meyerhardt JA, Hornick JL, Sethi NS, Cleary JMClinical cancer research : an official journal of the American Association for Cancer ResearchRAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer. Clin Cancer Res. 2024 Feb 12.Clin Cancer Res2024-02-12T00:00:002024RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer.true1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 16309001824145341Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, Qian ZR, Rubinson DA, Stampfer MJ, Giovannucci EL, Wolpin BMJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013 Nov 20; 31(33):4229-34.J Clin Oncol2013-10-21T00:00:002013Prediagnostic body mass index and pancreatic cancer survival.Authorship 6934838Authorship 3829563Authorship 7076412Authorship 715816123568716Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng KInvestigational new drugsMulti-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014 Feb; 32(1):113-22.Invest New Drugs2013-04-09T00:00:002013Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.10747032Xue D, Rubinson DA, Pannone BK, Yoo CJ, Wolin SLThe EMBO journalU snRNP assembly in yeast involves the La protein. EMBO J. 2000 Apr 03; 19(7):1650-60.EMBO J2000-04-03T00:00:002000U snRNP assembly in yeast involves the La protein.Authorship 732855224821822Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, Fuchs CS, McCleary NJ, Meyerhardt JA, Ng K, Schrag D, Sikora AL, Spicer BA, Killion L, Mamon H, Kimmelman ACThe oncologistPhase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8.Oncologist2014-05-12T00:00:002014Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.25261994Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK, Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ, Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S, Wactawski-Wende J, Manson JE, Pollak MN, Kimmelman AC, Souza A, Pierce K, Wang TJ, Gerszten RE, Fuchs CS, Vander Heiden MG, Wolpin BMNature medicineElevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014 10; 20(10):1193-1198.Nat Med2014-09-28T00:00:002014Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development.Authorship 7619841925403204Yuan C, Rubinson DA, Qian ZR, Wu C, Kraft P, Bao Y, Ogino S, Ng K, Clancy TE, Swanson RS, Gorman MJ, Brais LK, Li T, Stampfer MJ, Hu FB, Giovannucci EL, Kulke MH, Fuchs CS, Wolpin BMJournal of clinical oncology : official journal of the American Society of Clinical OncologySurvival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol. 2015 Jan 01; 33(1):29-35.J Clin Oncol2014-11-17T00:00:002014Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus.Authorship 7784172Authorship 4933962Authorship 3324122Authorship 802488425882375Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci DV, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou SH, Miller VAThe oncologistProspective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist. 2015 May; 20(5):499-507.Oncologist2015-04-16T00:00:002015Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Authorship 823149126226909Rubinson DA, Wolpin BMHematology/oncology clinics of North AmericaTherapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015 Aug; 29(4):761-76.Hematol Oncol Clin North Am2015-06-09T00:00:002015Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.Authorship 5497628Authorship 8583441126755275Yuan C, Clish CB, Wu C, Mayers JR, Kraft P, Townsend MK, Zhang M, Tworoger SS, Bao Y, Qian ZR, Rubinson DA, Ng K, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Ma J, Sesso HD, Anderson GL, Cochrane BB, Manson JE, Torrence ME, Kimmelman AC, Amundadottir LT, Vander Heiden MG, Fuchs CS, Wolpin BMJournal of the National Cancer InstituteCirculating Metabolites and Survival Among Patients With Pancreatic Cancer. J Natl Cancer Inst. 2016 Jun; 108(6):djv409.J Natl Cancer Inst2016-01-11T00:00:002016Circulating Metabolites and Survival Among Patients With Pancreatic Cancer.Authorship 4484281Authorship 8889921127052656Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, Erlich RL, Frampton GM, Chalmers ZR, Vergilio J, Rubinson DA, Sun JX, Chmielecki J, Yelensky R, Suh JH, Lipson D, George TJ, Elvin JA, Stephens PJ, Miller VA, Ross JS, Ali SMAnnals of oncology : official journal of the European Society for Medical OncologyComprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. Ann Oncol. 2016 07; 27(7):1336-41.Ann Oncol2016-04-06T00:00:002016Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.2Assistant Professor1Associate Professor0Full Professor27325858Yuan C, Qian ZR, Babic A, Morales-Oyarvide V, Rubinson DA, Kraft P, Ng K, Bao Y, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Buring JE, Cochrane BB, Chlebowski RT, Snetselaar LG, Manson JE, Fuchs CS, Wolpin BMJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. J Clin Oncol. 2016 08 20; 34(24):2899-905.J Clin Oncol2016-06-20T00:00:002016Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival.Authorship 9028605MQ28MotazQadanMotaz Qadan, M.D., Ph.D.155249Qadan, MotazAssociate Professor of SurgeryAuthorship 81153512134088Loureiro JJ, Rubinson DA, Bear JE, Baltus GA, Kwiatkowski AV, Gertler FBMolecular biology of the cellCritical roles of phosphorylation and actin binding motifs, but not the central proline-rich region, for Ena/vasodilator-stimulated phosphoprotein (VASP) function during cell migration. Mol Biol Cell. 2002 Jul; 13(7):2533-46.Mol Biol Cell2002-07-01T00:00:002002Critical roles of phosphorylation and actin binding motifs, but not the central proline-rich region, for Ena/vasodilator-stimulated phosphoprotein (VASP) function during cell migration.Authorship 974841828358654Yuan C, Morales-Oyarvide V, Babic A, Clish CB, Kraft P, Bao Y, Qian ZR, Rubinson DA, Ng K, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Cochrane BB, Manson JE, Fuchs CS, Wolpin BMJournal of clinical oncology : official journal of the American Society of Clinical OncologyCigarette Smoking and Pancreatic Cancer Survival. J Clin Oncol. 2017 Jun 01; 35(16):1822-1828.J Clin Oncol2017-03-30T00:00:002017Cigarette Smoking and Pancreatic Cancer Survival.12486224Tsai KY, MacPherson D, Rubinson DA, Nikitin AY, Bronson R, Mercer KL, Crowley D, Jacks TProceedings of the National Academy of Sciences of the United States of AmericaARF mutation accelerates pituitary tumor development in Rb+/- mice. Proc Natl Acad Sci U S A. 2002 Dec 24; 99(26):16865-70.Proc Natl Acad Sci U S A2002-12-16T00:00:002002ARF mutation accelerates pituitary tumor development in Rb+/- mice.11818069Tsai KY, MacPherson D, Rubinson DA, Crowley D, Jacks TCurrent biology : CBARF is not required for apoptosis in Rb mutant mouse embryos. Curr Biol. 2002 Jan 22; 12(2):159-63.Curr Biol2002-01-22T00:00:002002ARF is not required for apoptosis in Rb mutant mouse embryos.450 Brookline AveDana-Farber Cancer Institute450 Brookline AveBoston02215MAAuthorship 1015867228982112Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Bui JL, Yuan C, Qian ZR, Babic A, Da Silva A, Nowak JA, Khalaf N, Brais LK, Welch MW, Zellers CL, Ng K, Chang DT, Miksad RA, Bullock AJ, Tseng JF, Swanson RS, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Hornick JL, Ogino S, Fuchs CS, Hezel AF, Koong AC, Wolpin BMBritish journal of cancerLymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer. 2017 Dec 05; 117(12):1874-1882.Br J Cancer2017-10-05T00:00:002017Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.17988629Kwiatkowski AV, Rubinson DA, Dent EW, Edward van Veen J, Leslie JD, Zhang J, Mebane LM, Philippar U, Pinheiro EM, Burds AA, Bronson RT, Mori S, Fässler R, Gertler FBNeuronEna/VASP Is Required for neuritogenesis in the developing cortex. Neuron. 2007 Nov 08; 56(3):441-55.Neuron2007-11-08T00:00:002007Ena/VASP Is Required for neuritogenesis in the developing cortex.18026093Dent EW, Kwiatkowski AV, Mebane LM, Philippar U, Barzik M, Rubinson DA, Gupton S, Van Veen JE, Furman C, Zhang J, Alberts AS, Mori S, Gertler FBNature cell biologyFilopodia are required for cortical neurite initiation. Nat Cell Biol. 2007 Dec; 9(12):1347-59.Nat Cell Biol2007-11-18T00:00:002007Filopodia are required for cortical neurite initiation.Authorship 1022923229098284Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, Welch MW, Brais LK, Da Silva A, Li T, Li W, Masuda A, Yang J, Shi Y, Gu M, Masugi Y, Bui J, Zellers CL, Yuan C, Babic A, Khalaf N, Aguirre A, Ng K, Miksad RA, Bullock AJ, Chang DT, Tseng JF, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar M, Wollison B, Laing A, Hahn WC, Meyerson M, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Wolpin BMJAMA oncologyAssociation of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.JAMA Oncol2018-03-08T00:00:002018Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.12590264Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs LNature geneticsA lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003 Mar; 33(3):401-6.Nat Genet2003-02-18T00:00:002003A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference.Authorship 10404261029362938Hamada T, Khalaf N, Yuan C, Babic A, Morales-Oyarvide V, Qian ZR, Nowak JA, Ng K, Kraft P, Rubinson DA, Stampfer MJ, Giovannucci EL, Fuchs CS, Ogino S, Wolpin BMJournal of gastroenterologyStatin use and pancreatic cancer risk in two prospective cohort studies. J Gastroenterol. 2018 Aug; 53(8):959-966.J Gastroenterol2018-01-23T00:00:002018Statin use and pancreatic cancer risk in two prospective cohort studies.